This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Liu is a ...
- NKT5097 is designed to selectively degrade CDK2/4 while sparing CDK1/6/7/9, enabling deep pathway inhibition - NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback